Desogestrel
As of the edition of 20 October 2026, Desogestrel is a small molecule: marketed, first approved in 1982 (FR); acts on PGR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Desogen
- First approved
- 18 May 1982 (FR)
- Approvals on record
- 11 in 5 regions
- Holder of the most recent approval
- ORGANON FARMACĂUTICA LTDA.; 8 holders in all
- Registered trials
- 22, 3 stopped early
- Disease areas
- Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Heart and blood vessels; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Desogestrel.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PGR | Progesterone receptor | P06401 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 5 | 0 | 1 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 5 | 3 | 0 | 0 |
| Phase 4 | 6 | 1 | 2 | 1 |
| All trials | 22 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Organon | Applicant and Lead sponsor of trials | 1989 to now |